STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vertex Pharmaceuticals will pay $10 billion to acquire Crinetics Pharmaceuticals and its drug Palsonify, which launched last year and treats the rare endocrine disorder acromegaly.
- The deal also transfers other Crinetics candidates described as having "blockbuster potential if approved," including a late-stage therapy for congenital adrenal hyperplasia.
- This is the largest acquisition in Vertex's history, as the Boston-based drugmaker pursues next-generation products beyond its established cystic fibrosis portfolio.
- The transaction lands amid a broader surge in biotech M&A activity, flagged in STAT's parallel coverage headline describing a "biotech M&A boom."
Why it matters: For a company long identified with cystic fibrosis, a $10 billion move into rare endocrine disorders signals a deliberate strategic pivot — Vertex is writing its largest-ever acquisition check for a drug launched only last year plus pipeline candidates whose commercial value remains unproven.
.png)
